629424-188f25fd-8ffb-4f87-be55-5cccd3e008c8
Position
Director, Division of Translational Research, National Institute of Neurological Disorders and Stroke
Location
Rockville MD UNITED STATES
Bio
Dr. Amir Tamiz is the Associate Director at National Institute of Neurological Disorders and Stroke (NINDS) and the Director of the Division of Translational Research (DTR). The mission of DTR is to accelerate application of basic research findings to patient use for neurological disorders and stroke by providing funding, expertise, and resources to the research community. Dr. Tamiz and his team advance this mission – thru several flagship programs spanning therapeutics and device development, model development and screening, and biomarker discovery and validation. His team is also responsible for administration of Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Dr. Tamiz joined NINDS in 2012 and assumed leadership role for the NIH Blueprint Neurotherapeutics network (BPN) and Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program. Blueprint Neurotherapeutics network is a collaborative effort among 15 of the NIH institutes and centers, leveraging their resources to offer neuroscience researchers funding for drug discovery and development activities to confront major, cross-cutting challenges in neuroscience. The program has established an efficient pipeline between academia and industry advancing many projects from chemical optimization to Phase I clinical testing. Dr. Tamiz envisioned and launched the IGNITE program in 2014 which has created a contiguous source of support from discovery to preclinical development. IGNITE covers a suite of funding programs spanning assay development and therapeutic agent identification and characterization, pharmacodynamics and In vivo efficacy studies, and development and validation of translational model systems for drug discovery. Prior to joining NIH, Dr. Tamiz had held scientific and management positions in research and development of therapeutic programs at Corvas International (acquired by Dendreon), CovX (now part of Pfizer), and Alba Therapeutics. Dr. Tamiz received his Ph.D. at University of Oregon and conducted postdoctoral research at the Department of Neuroscience at Georgetown University Medical Center.